智飞生物：子公司带状疱疹mRNA疫苗临床试验获批

Core Viewpoint - The company announced that its subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trials of its shingles mRNA vaccine, which is aimed at preventing shingles [1] Group 1 - The approval of the shingles mRNA vaccine clinical trial is not expected to have a significant impact on the company's recent performance [1] - This project will help the company strengthen its research and development capabilities and enhance its pipeline reserves [1] - There is uncertainty regarding the subsequent clinical trial progress, results, and product launch, and the company will fulfill its information disclosure obligations based on R&D progress [1]